

CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XD000806 AGE/SEX :34 Years Male

: SANJM031089321

PATIENT ID

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

CLIENT PATIENT ID: ABHA NO

RECEIVED: 11/04/2024 09:12:15 REPORTED :24/04/2024 15:11:05

Test Report Status Results **Biological Reference Interval** Units **Final**

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

XRAY-CHEST

NO ABNORMALITY DETECTED **IMPRESSION**

ECG

NORMAL SINUS RHYTHM **ECG**

MEDICAL HISTORY

RELEVANT PRESENT HISTORY **NOT SIGNIFICANT** RELEVANT PAST HISTORY NOT SIGNIFICANT RELEVANT PERSONAL HISTORY **NOT SIGNIFICANT**

RELEVANT FAMILY HISTORY **ASTHMA CANCER**

OCCUPATIONAL HISTORY NOT SIGNIFICANT HISTORY OF MEDICATIONS NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

mts HEIGHT IN METERS 1.60 WEIGHT IN KGS. 73.0 Kgs

BMI 29 BMI & Weight Status as follows/sqmts

> Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE **NORMAL** PHYSICAL ATTITUDE **NORMAL**


P. V. Kapadia

Dr. Priyank Kapadia

Physician

Dr.Sahil .N.Shah

Page 1 Of 22







View Report



Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi,

Ahmedabad, 380015

Gujrat, India Tel: 079-48912999,079-48913999,079-48914999

Email: customercare.ahmedabad@agilus.in





Male

PATIENT NAME: SANJAY R. CHAUHAN REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XD000806 AGE/SEX :34 Years ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

PATIENT ID : SANJM031089321

CLIENT PATIENT ID: ABHA NO

RECEIVED: 11/04/2024 09:12:15 REPORTED :24/04/2024 15:11:05

Test Report Status Results **Biological Reference Interval** Units **Final**

OVERWEIGHT

GENERAL APPEARANCE / NUTRITIONAL

STATUS

BUILT / SKELETAL FRAMEWORK AVERAGE NORMAL FACIAL APPEARANCE **NORMAL** SKIN **NORMAL** UPPER LIMB LOWER LIMB **NORMAL NECK NORMAL**

NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER

NOT ENLARGED THYROID GLAND

NORMAL TEMPERATURE 80/MIN **PULSE** RESPIRATORY RATE **NORMAL**

CARDIOVASCULAR SYSTEM

PERICARDIUM

mm/Hg BP 118/74 MM HG

> (SITTING) **NORMAL**

APEX BEAT **NORMAL**

HEART SOUNDS S1, S2 HEARD NORMALLY

ABSENT MURMURS

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST **NORMAL** MOVEMENTS OF CHEST SYMMETRICAL **NORMAL** BREATH SOUNDS INTENSITY

BREATH SOUNDS QUALITY VESICULAR (NORMAL)

ADDED SOUNDS ABSENT

P. V. Kapadia

Dr. Priyank Kapadia

Physician

Dr.Sahil .N.Shah **Consultant Radiologist**





Page 2 Of 22

View Report



Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi,

Ahmedabad, 380015 Gujrat, India





CODE/NAME & ADDRESS : C000138364 ACCESSION NO : **0321XD000806** AGE/SEX : 34 Years Male

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : SANJM031089321 DRAWN :

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 11/04/2024 09:12:15

Test Report Status Final Results Biological Reference Interval Units

PER ABDOMEN

APPEARANCE NORMAL

LIVER NOT PALPABLE SPLEEN NOT PALPABLE

CENTRAL NERVOUS SYSTEM

HIGHER FUNCTIONS

CRANIAL NERVES

CEREBELLAR FUNCTIONS

SENSORY SYSTEM

MOTOR SYSTEM

REFLEXES

NORMAL

NORMAL

NORMAL

MUSCULOSKELETAL SYSTEM

SPINE NORMAL JOINTS NORMAL

BASIC EYE EXAMINATION

DISTANT VISION RIGHT EYE WITH GLASSES 6/12
DISTANT VISION LEFT EYE WITH GLASSES 6/12
NEAR VISION RIGHT EYE WITH GLASSES N/6
NEAR VISION LEFT EYE WITH GLASSES N/6
COLOUR VISION NORMAL

SUMMARY

RELEVANT HISTORY NOT SIGNIFICANT RELEVANT GP EXAMINATION FINDINGS NOT SIGNIFICANT

P. V. Rapadia

Dr.Sahil .N.Shah Consultant Radiologist

Dr.Priyank Kapadia Physician



Page 3 Of 22

View Details

View Report



Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi,

Ahmedabad, 380015 Gujrat, India





Male

PATIENT NAME: SANJAY R. CHAUHAN REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XD000806 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

PATIENT ID : SANJM031089321

CLIENT PATIENT ID: ABHA NO

AGE/SEX :34 Years

RECEIVED: 11/04/2024 09:12:15 REPORTED :24/04/2024 15:11:05

Test Report Status Results **Biological Reference Interval** Units **Final**

TRIGLYCERIDES:- HIGH, LDL:- HIGH, VLDL:- HIGH RELEVANT LAB INVESTIGATIONS

URIC ACID:- HIGH

RELEVANT NON PATHOLOGY DIAGNOSTICS NO ABNORMALITIES DETECTED

1) TRIGLYCERIDES:- HIGH, LDL:- HIGH, VLDL:- HIGH

ADV:- LOW FAT DIET, REGULAR PHYSICAL EXERCISE

2) URIC ACID:- HIGH

ADV:- PHYSICIAN OPINION

Comments

OUR PANEL DOCTORS FOR NON-PATHOLOGY TESTS:-

REMARKS / RECOMMENDATIONS

CHECK UP DONE BY: - DR. NAMRATA AGRAWAL (M.B.B.S)

REPORT REVIEWED BY:- DR. PRIYANK KAPADIYA (M.B.B.S DNB MEDICINE)

RADIOLOGIST: - DR. SAHIL N SHAH (M.D.RADIOLOGY)

P. V. Kapadia

Dr. Priyank Kapadia **Physician**

Dr.Sahil .N.Shah **Consultant Radiologist**

Page 4 Of 22

View Report



Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XD000806 AGE/SEX :34 Years Male ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

PATIENT ID F-703, LADO SARAI, MEHRAULISOUTH WEST

CLIENT PATIENT ID: **DELHI** ABHA NO **NEW DELHI 110030**

: SANJM031089321

RECEIVED: 11/04/2024 09:12:15 REPORTED :24/04/2024 15:11:05

Test Report Status Results Units **Final**

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ULTRASOUND ABDOMEN ULTRASOUND ABDOMEN

FATTY LIVER

TMT OR ECHO

8800465156

CLINICAL PROFILE

2D ECHO:-

- 1) NORMAL CHAMBERS AND VALVES.
- 2) GOOD LV SYSTOLIC FUNCTION. LVEF 60%. NO RWMA AT REST.
- 3) NO MR, AR, TR.
- 4) NORMAL LV COMPLIANCE.
- 5) NO PAH.
- 6) NO LV CLOT, VEGETATION OR PERICARDIAL EFFUSION.
- 7) IAS/IVS INTACT.

Interpretation(s)

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

P. V. Kapadia

Dr. Priyank Kapadia **Physician**

Dr.Sahil .N.Shah **Consultant Radiologist**





Page 5 Of 22

View Report



Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XD000806 AGE/SEX :34 Years

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : SANJM031089321 DRAWN

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 11/04/2024 09:12:15 DELHI

REPORTED :24/04/2024 15:11:05 ABHA NO **NEW DELHI 110030** 8800465156

Biological Reference Interval Test Report Status Results Units **Final**

| н | AEMATOLOGY - CBC | | |
|------------------------------------------------------------|------------------|--------------|----------|
| MEDI WHEEL FULL BODY HEALTH CHECK UP B | ELOW 40 MALE | | |
| BLOOD COUNTS,EDTA WHOLE BLOOD | | | |
| HEMOGLOBIN (HB) | 13.9 | 13.0 - 17.0 | g/dL |
| METHOD: PHOTOMETRIC MEASUREMENT | | | |
| RED BLOOD CELL (RBC) COUNT | 4.32 Low | 4.5 - 5.5 | mil/μL |
| METHOD : COULTER PRINCIPLE | 6.78 | 4.0 - 10.0 | thou/µL |
| WHITE BLOOD CELL (WBC) COUNT METHOD: COULTER PRINCIPLE | 0.76 | 4.0 - 10.0 | τησα/ με |
| PLATELET COUNT | 343 | 150 - 410 | thou/µL |
| METHOD : COULTER PRINCIPLE | | | |
| | | | |
| | | | |
| RBC AND PLATELET INDICES | | | |
| HEMATOCRIT (PCV) | 42.2 | 40.0 - 50.0 | % |
| METHOD : CALCULATED | | | |
| MEAN CORPUSCULAR VOLUME (MCV) | 97.8 | 83.0 - 101.0 | fL |
| METHOD: DERIVED PARAMETER FROM RBC HISTOGRAM | | | |
| MEAN CORPUSCULAR HEMOGLOBIN (MCH) | 32.1 High | 27.0 - 32.0 | pg |
| METHOD : CALCULATED MEAN CORPUSCULAR HEMOGLOBIN | 32.9 | 31.5 - 34.5 | g/dL |
| CONCENTRATION (MCHC) | 32.3 | 31.3 34.3 | 9/ 42 |
| METHOD : CALCULATED | | | |
| RED CELL DISTRIBUTION WIDTH (RDW) | 13.4 | 11.6 - 14.0 | % |
| METHOD: DERIVED PARAMETER FROM RBC HISTOGRAM MENTZER INDEX | 22.6 | | |
| METHOD : CALCULATED PARAMETER | 22.0 | | |
| MEAN PLATELET VOLUME (MPV) | 7.6 | 6.8 - 10.9 | fL |
| METHOD: DERIVED PARAMETER FROM PLATELET HISTOGRAM | | | |
| | | | |
| | | | |
| WBC DIFFERENTIAL COUNT | | | |
| NEUTROPHILS | 63 | 40 - 80 | % |
| METHOD: OPTICAL IMPEDENCE & MICROCSOPY | | | |
| LYMPHOCYTES | 26 | 20 - 40 | % |
| METHOD: OPTICAL IMPEDENCE & MICROCSOPY | | | |

Dr.Miral Gajera Consultant Pathologist





Page 6 Of 22

View Report

Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India Tel: 079-48912999,079-48913999,079-48914999 Email: customer care. ahmed abad@agilus. in





CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XD000806 AGE/SEX :34 Years Male ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

PATIENT ID : SANJM031089321

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 11/04/2024 09:12:15 **DELHI**

ABHA NO REPORTED :24/04/2024 15:11:05 **NEW DELHI 110030** 8800465156

| | i | i | |
|----------------------------------------|----------|----------------------|----------------|
| Test Report Status <u>Final</u> | Results | Biological Reference | Interval Units |
| | | | |
| MONOCYTES | 8 | 2.0 - 10.0 | % |
| METHOD: OPTICAL IMPEDENCE & MICROCSOPY | | | |
| EOSINOPHILS | 3 | 1.0 - 6.0 | % |
| METHOD: OPTICAL IMPEDENCE & MICROCSOPY | | | |
| BASOPHILS | 0 | 0 - 1 | % |
| METHOD: IMPEDANCE | | | |
| ABSOLUTE NEUTROPHIL COUNT | 4.27 | 2.0 - 7.0 | thou/μL |
| METHOD: CALCULATED | | | |
| ABSOLUTE LYMPHOCYTE COUNT | 1.76 | 1.0 - 3.0 | thou/μL |
| METHOD: CALCULATED PARAMETER | | | |
| ABSOLUTE MONOCYTE COUNT | 0.54 | 0.2 - 1.0 | thou/μL |
| METHOD: CALCULATED PARAMETER | | | |
| ABSOLUTE EOSINOPHIL COUNT | 0.20 | 0.02 - 0.50 | thou/μL |
| METHOD: CALCULATED | | | |
| ABSOLUTE BASOPHIL COUNT | 0.00 Low | 0.02 - 0.10 | thou/μL |
| METHOD: CALCULATED | | | |
| NEUTROPHIL LYMPHOCYTE RATIO (NLR) | 2.4 | | |
| METHOD: CALCULATED PARAMETER | | | |

MORPHOLOGY

NORMOCYTIC NORMOCHROMIC **RBC**

METHOD: MICROSCOPIC EXAMINATION

WBC NORMAL MORPHOLOGY METHOD: MICROSCOPIC EXAMINATION

PLATELETS ADEQUATE

METHOD: MICROSCOPIC EXAMINATION **REMARKS**

NO PREMATURE CELLS ARE SEEN. MALARIAL PARASITE NOT DETECTED METHOD: MICROSCOPIC EXAMINATION

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

Dr.Miral Gajera **Consultant Pathologist**



Page 7 Of 22

View Report



Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi,

Ahmedabad, 380015



8800465156



PATIENT NAME: SANJAY R. CHAUHAN REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XD000806 AGE/SEX :34 Years

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : SANJM031089321 DRAWN

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID:

RECEIVED: 11/04/2024 09:12:15 **DELHI** ABHA NO REPORTED :24/04/2024 15:11:05 **NEW DELHI 110030**

Test Report Status Results **Biological Reference Interval** Units **Final**

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr.Miral Gajera **Consultant Pathologist**



Page 8 Of 22

View Report



Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





mm at 1 hr

REF. DOCTOR: SELF **PATIENT NAME: SANJAY R. CHAUHAN**

CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XD000806 AGE/SEX :34 Years

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : SANJM031089321

CLIENT PATIENT ID:

ABHA NO

RECEIVED: 11/04/2024 09:12:15

REPORTED :24/04/2024 15:11:05

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD

E.S.R 05 0 - 14

METHOD: WESTERGREN METHOD

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE **BLOOD**

HBA1C 5.5 Non-diabetic: < 5.7 %

> Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5Therapeutic goals: < 7.0 Action suggested : > 8.0

(ADA Guideline 2021)

METHOD: HPLC

ESTIMATED AVERAGE GLUCOSE(EAG) < 116.0 mg/dL 111.2

Interpretation(s)
ERYTHROCYTE SEDIMENTATION RATE (ESR),EDTA BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an ondition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc.), Hypercholesterolemia False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

Dr.Miral Gaiera Consultant Pathologist



Page 9 Of 22

View Report



Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi,

Ahmedabad, 380015





REF. DOCTOR: SELF **PATIENT NAME: SANJAY R. CHAUHAN**

CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XD000806 AGE/SEX :34 Years

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : SANJM031089321 DRAWN

F-703, LADO SARAI, MEHRAULISOUTH WEST

RECEIVED: 11/04/2024 09:12:15 CLIENT PATIENT ID: **DELHI** ABHA NO REPORTED :24/04/2024 15:11:05 **NEW DELHI 110030**

Test Report Status Results **Biological Reference Interval Final** Units

8800465156

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition.

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes.3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

- 2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :

- 1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days. 2.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.
- 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

 4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
- b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
- c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Dr.Miral Gajera **Consultant Pathologist**





Page 10 Of 22

View Report



Agilus Diagnostics Ltd Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XD000806 AGE/SEX :34 Years

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : SANJM031089321 DRAWN

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 11/04/2024 09:12:15

DELHI ABHA NO REPORTED :24/04/2024 15:11:05 **NEW DELHI 110030** 8800465156

Test Report Status Results **Biological Reference Interval** Units **Final**

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

TYPE O **ABO GROUP**

METHOD: TUBE AGGLUTINATION

POSITIVE RH TYPE

METHOD: TUBE AGGLUTINATION

Interpretation(s)
ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

Dr.Miral Gajera **Consultant Pathologist**



Page 11 Of 22

View Report



Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : SANJM031089321

CLIENT PATIENT ID: ABHA NO : DRAWN :

:

RECEIVED :11/04/2024 09:12:15 REPORTED :24/04/2024 15:11:05

Test Report Status <u>Final</u> Results Biological Reference Interval Units

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) **100 High** 74 - 99 mg/dL

METHOD: HEXOKINASE

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR) 138 70 - 140 mg/dL

METHOD: HEXOKINASE

LIPID PROFILE WITH CALCULATED LDL, SERUM

CHOLESTEROL, TOTAL 184 Desirable: < 200 mg/dL

BorderlineHigh: 200 - 239

High: > or = 240

 ${\tt METHOD}: {\tt ENZYMATIC}, {\tt COLORIMETRIC}$

TRIGLYCERIDES 176 High Desirable: < 150 mg/dL

BorderlineHigh: 150 - 199

High: 200 - 499

 $\label{eq:Very High:} Very \; \text{High:} \; > \; \text{or} \; = \; 500$ $\text{METHOD:} \; \text{ENZYMATIC,} \; \text{COLORIMETRIC}$

HDL CHOLESTEROL 40 < 40 Low mg/dL

> or = 60 High

CHOLESTEROL LDL **109 High** Adult levels: mg/dL

Optimal < 100

Near optimal/above optimal:

100-129

Borderline high: 130-159

High: 160-189 Very high: = 190

NON HDL CHOLESTEROL 144 High Desirable: Less than 130

Desirable: Less than 130 mg/dL Above Desirable: 130 - 159

Borderline High: 160 - 189

High: 190 - 219

Very high: > or = 220

VERY LOW DENSITY LIPOPROTEIN **35.2 High** < or = 30 mg/dL

Dr.Miral Gajera Consultant Pathologist



Page 12 Of 22

View Details

View Report



Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi,

Ahmedabad, 380015

Gujrat, India





PATIENT NAME: SANJAY R. CHAUHAN REF. DOCTOR: SELF CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XD000806 AGE/SEX :34 Years Male ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID DRAWN : SANJM031089321 F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 11/04/2024 09:12:15 **DELHI** ABHA NO REPORTED :24/04/2024 15:11:05 **NEW DELHI 110030** 8800465156

| Test Report Status | <u>Final</u> | Results | Biological Reference Interval | Units |
|--------------------|--------------|----------|-----------------------------------------------------------------------------------------|-------|
| CHOL/HDL RATIO | | 4.6 High | 3.3 - 4.4 | |
| LDL/HDL RATIO | | 2.7 | 0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk | |

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

| A.CAD with > 1 feature of high risk group | | | |
|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|
| B. CAD with > 1 feature of Very high risk g | roup or recurrent ACS (within 1 year) despite LDL-C < or = | | |
| 50 mg/dl or polyvascular disease | | | |
| 1. Established ASCVD 2. Diabetes with 2 n | najor risk factors or evidence of end organ damage 3. | | |
| Familial Homozygous Hypercholesterolemia | a | | |
| 1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ | | | |
| damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary | | | |
| Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque | | | |
| 2 major ASCVD risk factors | | | |
| 0-1 major ASCVD risk factors | | | |
| rosclerotic cardiovascular disease) Risk Fa | ctors | | |
| 1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use | | | |
| Family history of premature ASCVD 4. High blood pressure | | | |
| 5. Low HDL | | | |
| , | B. CAD with > 1 feature of Very high risk g 50 mg/dl or polyvascular disease 1. Established ASCVD 2. Diabetes with 2 m Familial Homozygous Hypercholesterolemia 1. Three major ASCVD risk factors. 2. Dia damage. 3. CKD stage 3B or 4. 4. LDL > 10 Artery Calcium - CAC > 300 AU. 7. Lipopra 2 major ASCVD risk factors 0-1 major ASCVD risk factors rosclerotic cardiovascular disease) Risk Fa in males and > or = 55 years in females | | |

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

| Risk Group | Treatment Goals | | Consider Drug Therapy | |
|-------------------------------|------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|-----------------------|-----------------|
| | LDL-C (mg/dl) | Non-HDL (mg/dl) | LDL-C (mg/dl) | Non-HDL (mg/dl) |
| Extreme Risk Group Category A | <50 (Optional goal < OR = 30) | < 80 (Optional goal <or 60)<="" =="" td=""><td>>OR = 50</td><td>>OR = 80</td></or> | >OR = 50 | >OR = 80 |
| Extreme Risk Group Category B | <or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>> 30</td><td>>60</td></or></td></or> | <or 60<="" =="" td=""><td>> 30</td><td>>60</td></or> | > 30 | >60 |
| Very High Risk | <50 | <80 | >OR= 50 | >OR= 80 |
| High Risk | <70 | <100 | >OR= 70 | >OR= 100 |
| Moderate Risk | <100 | <130 | >OR= 100 | >OR= 130 |
| Low Risk | <100 | <130 | >OR= 130* | >OR= 160 |

^{*}After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

Dr.Miral Gajera **Consultant Pathologist**





Page 13 Of 22

View Report

PERFORMED AT: Agilus Diagnostics Ltd

Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi,

Ahmedabad, 380015

Gujrat, India



8800465156



PATIENT NAME: SANJAY R. CHAUHAN REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XD000806 AGE/SEX :34 Years

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : SANJM031089321

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 11/04/2024 09:12:15

DELHI REPORTED :24/04/2024 15:11:05 ABHA NO **NEW DELHI 110030**

| | j | į | |
|----------------------------------------------------------------------------------|-----------|-----------------------------|----------|
| Test Report Status <u>Final</u> | Results | Biological Reference Interv | al Units |
| BILIRUBIN, TOTAL | 0.73 | Upto 1.2 | mg/dL |
| BILIRUBIN, DIRECT | 0.28 High | Upto 0.2 | mg/dL |
| METHOD : DIAZO COLORIMETRIC | | · | |
| BILIRUBIN, INDIRECT | 0.45 | 0.00 - 1.00 | mg/dL |
| TOTAL PROTEIN METHOD: COLORIMETRIC | 8.1 | 6.4 - 8.3 | g/dL |
| ALBUMIN | 5.0 | 3.5 - 5.2 | g/dL |
| METHOD: BROMOCRESOL GREEN | 2.4 | 2.0.4.4 | 7.11 |
| GLOBULIN | 3.1 | 2.0 - 4.1 | g/dL |
| ALBUMIN/GLOBULIN RATIO | 1.6 | 1.0 - 2.0 | RATIO |
| ASPARTATE AMINOTRANSFERASE(AST/SGOT) METHOD: IFCC WITHOUT PYRIDOXAL-5-PHOSPHATE | 22 | 0 - 40 | U/L |
| ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: IFCC WITHOUT PYRIDOXAL-5-PHOSPHATE | 37 | 0 - 41 | U/L |
| ALKALINE PHOSPHATASE METHOD: COLORIMETRIC | 123 | 40 - 129 | U/L |
| GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: ENZYMATIC, COLORIMETRIC | 30 | 8 - 61 | U/L |
| LACTATE DEHYDROGENASE METHOD: UV ASSAY METHOD | 197 | 135 - 225 | U/L |
| BLOOD UREA NITROGEN (BUN), SERUM | | | |
| BLOOD UREA NITROGEN | 6 | 6 - 20 | mg/dL |
| CREATININE, SERUM | | | |
| CREATININE METHOD: JAFFE ALKALINE PICRATE | 0.59 Low | 0.90 - 1.30 | mg/dL |
| BUN/CREAT RATIO | | | |
| BUN/CREAT RATIO | 10.17 | 5.0 - 15.0 | |

Dr.Miral Gajera Consultant Pathologist



Page 14 Of 22





Agilus Diagnostics Ltd Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India Tel: 079-48912999,079-48913999,079-48914999 Email: customer care. a hmed abad@agilus. in





CODE/NAME & ADDRESS: C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

ACCESSION NO: 0321XD000806

PATIENT ID : SANJM031089321

CLIENT PATIENT ID: ABHA NO

AGE/SEX :34 Years

Male

RECEIVED: 11/04/2024 09:12:15 REPORTED :24/04/2024 15:11:05

| Test Report Status | Final | Results | Biological Reference Interval | Units |
|-----------------------|-------|---------|-------------------------------|-------|
| . cot itopoi t otatao | шш | | Didiogical Reference Interval | • |

| URIC ACID | , SERUM |
|-----------|---------|
|-----------|---------|

| URIC ACID | 7.5 High | 3.4 - 7.0 | mg/dL |
|-----------|----------|-----------|-------|
| | | | |

TOTAL PROTEIN, SERUM

| TOTAL PROTEIN | 8.1 | 6.4 - 8.3 | g/dL |
|----------------------|-----|-----------|------|
| METHOD: COLORIMETRIC | | | |

ALBUMIN, SERUM

GLOBULIN

| ALBUMIN | 5.0 | 3.5 - 5.2 | g/dL |
|---------------------------|-----|-----------|------|
| METHOD: BROMOCRESOL GREEN | | | |

| GLOBULIN | 3.1 | 2.0 - 4.1 | g/dL |
|----------|-----|-----------|------|

ELECTROLYTES (NA/K/CL), SERUM

| SODIUM, SERUM | 138.9 | 136 - 145 | mmol/L |
|------------------------------|-------|-----------|--------|
| METHOD: ISE POTASSIUM, SERUM | 4.58 | 3.3 - 5.1 | mmol/L |
| METHOD : ISE CHLORIDE, SERUM | 98.7 | 98 - 106 | mmol/L |

METHOD: ION SELECTIVE ELECTRODE TECHNOLOGY

Interpretation(s)

| Sodium | Potassium | Chloride |
|--------|-----------|----------|
| | | |

Dr.Miral Gajera Consultant Pathologist



Page 15 Of 22

View Report



Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India Tel: 079-48912999,079-48913999,079-48914999 Email: customer care. ahmed abad@agilus. in





CODE/NAME & ADDRESS : C000138364 ACCESSION NO : **0321XD000806** AGE/SEX : 34 Years Male

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : SANJM031089321 DRAWN

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 11/04/2024 09:12:15

DELHI

NEW DELHI 110030

ABHA NO : REPORTED : 24/04/2024 15:11:05

8800465156

Test Report Status <u>Final</u> Results Biological Reference Interval Units

Decreased in: CCF. cirrhosis. Decreased in: Low potassium Decreased in: Vomiting, diarrhea. vomiting, diarrhea, excessive intake, prolonged vomiting or diarrhea, renal failure combined with salt sweating, salt-losing RTA types I and II, deprivation, over-treatment with nephropathy, adrenal insufficiency, hyperaldosteronism, Cushing's diuretics, chronic respiratory acidosis, nephrotic syndrome, water syndrome, osmotic diuresis (e.g. diabetic ketoacidosis, excessive intoxication, SIADH. Drugs: hyperglycemia), alkalosis, familial sweating, SIADH, salt-losing thiazides, diuretics, ACE inhibitors, periodic paralysis,trauma nephropathy, porphyria, expansion of chlorpropamide,carbamazepine,anti (transient). Drugs: Adrenergic agents, extracellular fluid volume, depressants (SSRI), antipsychotics. adrenalinsufficiency, diuretics. hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics. Increased in: Dehydration Increased in: Massive hemolysis, Increased in: Renal failure, nephrotic severe tissue damage, rhabdomyolysis, syndrome, RTA, dehydration, (excessivesweating, severe vomiting or diarrhea), diabetes acidosis, dehydration, renal failure. overtreatment with Addison's disease, RTA type IV, saline, hyperparathyroidism, diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate hyperkalemic familial periodic insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory water intake. Drugs: steroids, paralysis. Drugs: potassium salts, licorice.oral contraceptives. potassium- sparing diuretics, NSAIDs, alkalosis, hyperadrenocorticism. beta-blockers, ACE inhibitors, high-Drugs: acetazolamide.androgens. dose trimethoprim-sulfamethoxazole. hydrochlorothiazide, salicylates. Interferences: Severe lipemia or Interferences: Hemolysis of sample, Interferences:Test is helpful in hyperproteinemi, if sodium analysis delayed separation of serum, assessing normal and increased anion involves a dilution step can cause prolonged fist clenching during blood gap metabolic acidosis and in spurious results. The serum sodium drawing, and prolonged tourniquet distinguishing hypercalcemia due to falls about 1.6 mEq/L for each 100 placement. Very high WBC/PLT counts hyperparathyroidism (high serum mg/dL increase in blood glucose. may cause spurious. Plasma potassium chloride) from that due to malignancy levels are normal. (Normal serum chloride)

Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in:Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease,

Decreased in "Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease, malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

individuals.Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE. SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver,liver cancer,kidney failure,hemolytic anemia,pancreatitis,hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas.It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis,sometimes due to a viral infection,ischemia to the liver,chronic

Dr.Miral Gajera Consultant Pathologist



Page 16 Of 22

View Details

View Report



Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XD000806 AGE/SEX :34 Years ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI NEW DELHI 110030

8800465156

PATIENT ID : SANJM031089321

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 11/04/2024 09:12:15

REPORTED: 24/04/2024 15:11:05

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.Higher-than-normal levels may be due to:Chronic inflammation or infection,including HIV and hepatitis B or C,Multiple myeloma,Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic

syndrome, Protein-losing enteropathy etc. **Albumin** is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels: Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic

syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. **Higher-than-normal levels may be due to:** Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr.Miral Gajera **Consultant Pathologist**



Page 17 Of 22

View Report

PERFORMED AT: Agilus Diagnostics Ltd

Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XD000806 AGE/SEX :34 Years ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : SANJM031089321

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 11/04/2024 09:12:15

REPORTED :24/04/2024 15:11:05

Test Report Status Results Biological Reference Interval Units **Final**

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

PHYSICAL EXAMINATION, URINE

COLOR Yellow **APPEARANCE** Clear

CHEMICAL EXAMINATION, URINE

| PH | 5.5 | 4.7 - 7.5 |
|---------------------------------------|--------------|---------------|
| METHOD: REFLECTANCE SPECTROPHOTOMETRY | | |
| SPECIFIC GRAVITY | 1.010 | 1.003 - 1.035 |
| METHOD: REFLECTANCE SPECTROPHOTOMETRY | | |
| PROTEIN | NOT DETECTED | NOT DETECTED |
| METHOD: REFLECTANCE SPECTROPHOTOMETRY | | |
| GLUCOSE | NOT DETECTED | NEGATIVE |
| METHOD: REFLECTANCE SPECTROPHOTOMETRY | | |
| KETONES | NOT DETECTED | NOT DETECTED |
| METHOD: REFLECTANCE SPECTROPHOTOMETRY | | |
| BLOOD | NOT DETECTED | NOT DETECTED |
| METHOD: REFLECTANCE SPECTROPHOTOMETRY | | |
| BILIRUBIN | NOT DETECTED | NOT DETECTED |
| METHOD: REFLECTANCE SPECTROPHOTOMETRY | | |
| UROBILINOGEN | NORMAL | NORMAL |
| METHOD: REFLECTANCE SPECTROPHOTOMETRY | | |
| NITRITE | NOT DETECTED | NOT DETECTED |
| METHOD: REFLECTANCE SPECTROPHOTOMETRY | | |
| LEUKOCYTE ESTERASE | NOT DETECTED | NOT DETECTED |

MICROSCOPIC EXAMINATION, URINE

METHOD: REFLECTANCE SPECTROPHOTOMETRY

| RED BLOOD CELLS | NOT DETECTED | NOT DETECTED | /HPF |
|---------------------------------|--------------|--------------|------|
| METHOD: MICROSCOPIC EXAMINATION | | | |
| PUS CELL (WBC'S) | 0-1 | 0-5 | /HPF |
| METHOD: MICROSCOPIC EXAMINATION | | | |
| EPITHELIAL CELLS | 1-2 | 0-5 | /HPF |

Dr.Miral Gajera **Consultant Pathologist**



Page 18 Of 22

View Report



Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi,

Ahmedabad, 380015 Gujrat, India





PATIENT NAME: SANJAY R. CHAUHAN REF. DOCTOR: SELF CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XD000806 AGE/SEX :34 Years Male ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID DRAWN : SANJM031089321 F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 11/04/2024 09:12:15 **DELHI** ABHA NO REPORTED :24/04/2024 15:11:05 **NEW DELHI 110030**

Test Report Status Results **Biological Reference Interval** Units **Final**

METHOD: MICROSCOPIC EXAMINATION

8800465156

NOT DETECTED **CASTS**

METHOD: MICROSCOPIC EXAMINATION

NOT DETECTED **CRYSTALS**

METHOD: MICROSCOPIC EXAMINATION

BACTERIA NOT DETECTED NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

YEAST **NOT DETECTED** NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION MICROSCOPIC EXAMINATION OF URINE IS CARRIED OUT ON REMARKS

CENTRIFUGED URINARY SEDIMENT.

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

| Presence of | Conditions | | | |
|-------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|--|--|--|
| Proteins | Inflammation or immune illnesses | | | |
| Pus (White Blood Cells) | Urinary tract infection, urinary tract or kidney stone, tumors or any kind | | | |
| | of kidney impairment | | | |
| Glucose | Diabetes or kidney disease | | | |
| Ketones | Diabetic ketoacidosis (DKA), starvation or thirst | | | |
| Urobilinogen | Liver disease such as hepatitis or cirrhosis | | | |
| Blood | Renal or genital disorders/trauma | | | |
| Bilirubin | Liver disease | | | |
| Erythrocytes | Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urina | | | |
| | tract infection and glomerular diseases | | | |
| Leukocytes | Urinary tract infection, glomerulonephritis, interstitial nephritis either | | | |
| | acute or chronic, polycystic kidney disease, urolithiasis, contamination by | | | |
| | genital secretions | | | |
| Epithelial cells Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents | | | | |
| | bladder catheters for prolonged periods of time | | | |
| | | | | |
| Granular Casts Low intratubular pH, high urine osmolality and sodium conce | | | | |
| | interaction with Bence-Jones protein | | | |
| Hyaline casts | Physical stress, fever, dehydration, acute congestive heart failure, renal | | | |
| | diseases | | | |

Dr.Miral Gajera **Consultant Pathologist**



Page 19 Of 22

View Report



Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi,

Ahmedabad, 380015

Gujrat, India





PATIENT NAME: SANJAY R. CHAUHAN REF. DOCTOR: SELF CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XD000806 AGE/SEX :34 Years ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : SANJM031089321 F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 11/04/2024 09:12:15 DELHI REPORTED :24/04/2024 15:11:05 ABHA NO **NEW DELHI 110030** 8800465156

| Interval Units | , |
|-----------------------|-------------|
| Inte | erval Units |

| Calcium oxalate | Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Uric acid | arthritis |
| Bacteria | Urinary infectionwhen present in significant numbers & with pus cells. |
| Trichomonas vaginalis | Vaginitis, cervicitis or salpingitis |

Dr.Miral Gajera Consultant Pathologist



Page 20 Of 22





Agilus Diagnostics Ltd Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : SANJM031089321 DRAWN :

F-703, LADO SARAI, MEHRAULISOUTH WEST

CLIENT PATIENT ID:

NEW DELHI 110030

RECEIVED : 11/04/2024 09:12:15

REPORTED : 24/04/2024 15:11:05

Test Report Status <u>Final</u> Results Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

THYROID PANEL, SERUM

| T3 | 99.90 | 80.0 - 200.0 | ng/dL |
|----------------------|-------|---------------|--------|
| METHOD: ECLIA | | | |
| T4 | 5.68 | 5.10 - 14.10 | μg/dL |
| METHOD: ECLIA | | | |
| TSH (ULTRASENSITIVE) | 1.590 | 0.270 - 4.200 | μIU/mL |

METHOD : ECLIA

8800465156

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

| Sr. No. | TSH | Total T4 | FT4 | Total T3 | Possible Conditions |
|---------|------------|----------|--------|----------|----------------------------------------------------------------------------|
| 1 | High | Low | Low | Low | (1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3) |
| | | | | | Post Thyroidectomy (4) Post Radio-Iodine treatment |
| 2 | High | Normal | Normal | Normal | (1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid |
| | | | | | hormone replacement therapy (3) In cases of Autoimmune/Hashimoto |
| | | | | | thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical |
| | | | | | inflammation, drugs like amphetamines, Iodine containing drug and |
| | | | | | dopamine antagonist e.g. domperidone and other physiological reasons. |
| 3 | Normal/Low | Low | Low | Low | (1) Secondary and Tertiary Hypothyroidism |
| 4 | Low | High | High | High | (1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre |
| | | | | | (3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid |
| | | | | | hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 |
| | | | | | replacement therapy (7) First trimester of Pregnancy |
| 5 | Low | Normal | Normal | Normal | (1) Subclinical Hyperthyroidism |

Dr.Miral Gajera Consultant Pathologist



Page 21 Of 22

View Details

View Report

PERFORMED AT:
Agilus Diagnostics Ltd

Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi,

Ahmedabad, 380015 Gujrat, India





CODE/NAME & ADDRESS : C000138364 ACCESSION NO : **0321XD000806** AGE/SEX : 34 Years Male

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : SANJM031089321 DRAWN :

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 11/04/2024 09:12:15

NEW DELHI 110030 ABHA NO : REPORTED : 24/04/2024 15:11:05 8800465156

Test Report Status <u>Final</u> Results Biological Reference Interval Units

| 6 | High | High | High | High | (1) TSH secreting pituitary adenoma (2) TRH secreting tumor |
|---|------------|--------|--------|--------|----------------------------------------------------------------------|
| 7 | Low | Low | Low | Low | (1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent |
| | | | | | treatment for Hyperthyroidism |
| 8 | Normal/Low | Normal | Normal | High | (1) T3 thyrotoxicosis (2) Non-Thyroidal illness |
| 9 | Low | High | High | Normal | (1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies |

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. **NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.**TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

End Of Report
Please visit www.agilusdiagnostics.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Ltd

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Dr.Miral Gajera Consultant Pathologist





Page 22 Of 22

View Details

View Report



Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India

